http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2011200558-A1
Outgoing Links
Predicate | Object |
---|---|
assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_602e84c727e976e9f361ebbb6b5781fd |
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D209-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-56 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-05 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-212 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-21 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-05 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-14 |
filingDate | 2009-08-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e116ee91f15ae3ee4b71fb579c0f9cad http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b12d721ba38cbdb79dbe883f25ae0193 |
publicationDate | 2011-08-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | US-2011200558-A1 |
titleOfInvention | Treatment or Prevention of Hepatitis C with Immunomodulator Compounds |
abstract | A method of treatment for treating or preventing hepatitis C (HepC) in a target subject, including administering to the target subject an effective amount of an immunomodulator compound of Formula A wherein, n is 1 or 2, R is hydrogen, acyl, alkyl or a peptide fragment, and X is an aromatic or heterocyclic amino acid or a derivative thereof, wherein; (i) the immunomodulator compound is administered to the subject at a dosage of greater than 0.001 mg/kg; (ii) the immunomodulator compound is administered in a combination treatment regimen further including administration to the subject of ribavirin, wherein the immunomodulator compound and the ribavirin are administered to the subject separately or together in the treatment regimen; (iii) the immunomodulator compound is administered in a combination treatment regimen with a specifically targeted antiviral therapy for hepatitis C (STAT-C) agent, wherein the immunomodulator compound and the STAT-C agent are administered to the subject separately or together in the treatment regimen; or (iv) a combination of at least two of (i), (ii), and (iii). |
priorityDate | 2008-08-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 222.